Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Polyomavirus Infections
Conditions
Polyomavirus Infections
Trial Timeline
Sep 1, 2004 → Mar 1, 2010
NCT ID
NCT00160966About Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus
Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus is a approved stage product being developed by Astellas Pharma for Polyomavirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00160966. Target conditions include Polyomavirus Infections.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00160966 | Approved | Completed |
Competing Products
1 competing product in Polyomavirus Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| FK778 | Astellas Pharma | Phase 2 | 52 |